Cardinal Health added a high‑capacity production line to its Center for Theranostics Advancement in Indianapolis, Indiana, quadrupling weekly Ac‑225 output since the end of 2024. The expansion was completed prior to the announcement and now supports more than 15 ongoing clinical trials worldwide.
The new capacity strengthens Cardinal Health’s position as a leading provider of radiopharmaceuticals and supports its specialty‑healthcare platform strategy, which relies on in‑house manufacturing to secure high‑margin, high‑growth product lines. By addressing the limited availability of Ac‑225—a bottleneck for targeted alpha‑therapy development—the company is better positioned to meet the growing demand for these therapies.
The expanded output will support future commercial production of targeted alpha‑therapy drugs for cancers such as prostate, neuroendocrine, breast, colon, melanoma, and lymphoma. Cardinal Health’s partnership with TerraPower Isotopes and the Center for Theranostics Advancement’s operational history since 2019 underpin the company’s ability to deliver cGMP‑compliant Ac‑225 at commercial scale.
"Expanding our Ac‑225 production capacity is a critical step forward for the industry and for patients. As targeted alpha therapies progress through clinical trials, reliable access to Ac‑225 remains essential. This expanded capacity strengthens our ability to meet customer needs today while preparing for significantly larger commercial volumes that may occur in the coming years," said Shane Thrasher, Vice President of Radiopharmaceutical Manufacturing at Cardinal Health. "The reliable availability of Ac‑225 is essential for advancing targeted alpha therapies and enabling innovation in clinical research. Cardinal Health's commitment to expanding production capacity helps ensure a more robust supply chain, accelerating our ability to drive progress and deliver new treatment options to patients," added Eric Bischoff, Chief of Product Development and Operations at RayzeBio.
The expansion enables pharmaceutical innovators to advance clinical trials and develop new treatments, reinforcing Cardinal Health’s role in the growing theranostics market and supporting its broader strategy to capture high‑growth opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.